Retatrutide vs tirzepatide: what's the difference?

The core difference is how many hormone pathways each drug targets. Tirzepatide is a dual agonist (GLP-1 and GIP) and is available today under physician supervision. Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon) that is not FDA-approved and not available by prescription. So the practical difference for you right now is availability: tirzepatide is a real, monitored option; retatrutide is not.

Mechanism

Tirzepatide combines GLP-1 and GIP activity to reduce appetite and improve blood-sugar handling. Retatrutide adds a third target — the glucagon receptor — studied for increasing energy expenditure. More pathways is not automatically 'better' for a given person; it also changes the side-effect and safety picture, which is exactly what trials are still evaluating.

Availability and safety

Tirzepatide has established dosing and is dispensed by licensed U.S. pharmacies with physician oversight. Retatrutide has no approved dose and no legal supply; anything sold as retatrutide online is unregulated. If you're comparing the two to decide what to start, tirzepatide (or semaglutide) is the appropriate conversation to have with a physician today.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/answers.